Compare GSK plc (GSK) vs Honeywell International Inc (HON) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Honeywell Technologies (HON) trades at $222.68, showing modest daily gains of 0.19%. The stock recently completed a 2:1 reverse stock split on June 29, 2026, and updated its 2026 EPS guidance accordingly. Technically, the stock faces immediate resistance at $224 with support at $222, while the broader technical signal remains bearish. Fundamentally, the company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $2.58 beating expectations of $2.43. However, revenue declined slightly from $38.5B in 2024 to $37.4B in 2025, and net income margins compressed from 14.81% to 12.63% over the same period.

The investment outlook presents a mixed picture. Analyst consensus remains strongly bullish with 19 buy ratings and a $368.55 price target, representing 65% upside potential. However, near-term challenges include weaker process automation performance, post-spinoff execution uncertainty, and margin pressure. The company's renewed focus on automation and industrial technology post-aerospace spinoff offers long-term growth potential, but investors face transitional volatility and integration risks.